Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMNF4UH)

• Drug Name: Liprotamase Drug Info
• Synonyms: LY3031642

Indication

Disease Entry	ICD 11	Status	REF
Cystic fibrosis	CA25	Phase 3	[1]

• Cross-matching ID: TTD Drug ID: DMNF4UH

Molecule-Related Drug Atlas

Drug(s) Targeting Chymotrypsin (CTR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Pancrecarb	DMOML9Q	Pancreatic malfunction	DC30-DC3Z	NDA filed	[3]
CM-AT	DMLMN2F	Attention deficit hyperactivity disorder	6A05.Z	Phase 3	[4]
POP-1	DMVTKCX	Solid tumour/cancer	2A00-2F9Z	Investigative	[3]
JBP-1	DM0KMPN	Solid tumour/cancer	2A00-2F9Z	Investigative	[3]

Drug(s) Targeting Pancreatic alpha-amylase (AMY2A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Pancrecarb	DMOML9Q	Pancreatic malfunction	DC30-DC3Z	NDA filed	[5]
Beta-D-Glucose	DM5IHYP	Discovery agent	N.A.	Investigative	[6]
Pyroglutamic Acid	DMROZUA	Discovery agent	N.A.	Investigative	[6]
Acanthus ilicifolius Linn	DMZDFRI	Discovery agent	N.A.	Investigative	[7]
6-Deoxy-Alpha-D-Glucose	DM9HBY5	Discovery agent	N.A.	Investigative	[6]
Acarbose Derived Hexasaccharide	DMS9COH	Discovery agent	N.A.	Investigative	[6]
Maltosyl-Alpha (1,4)-D-Gluconhydroximo-1,5-Lactam	DMMY542	Discovery agent	N.A.	Investigative	[8]
Hydroxycitric acid	DMY0A9E	Discovery agent	N.A.	Investigative	[9]
Alpha-acarviosinyl-(1-->9)-3-alpha-D-glucopyranosylpropen	DM4IXUQ	Discovery agent	N.A.	Investigative	[10]
Alpha-acarviosinyl-(1-->7)-3-alpha-D-glucopyranosylpropen	DMHV14R	Discovery agent	N.A.	Investigative	[10]

Drug(s) Targeting Pancreatic triacylglycerol lipase (PNLIP)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Orlistat	DMRJSP8	Obesity	5B81	Approved	[11]
Dalbavancin	DMGMNH3	Bacterial infection	1A00-1C4Z	Approved	[12]
Pancrecarb	DMOML9Q	Pancreatic malfunction	DC30-DC3Z	NDA filed	[5]
MS-1819	DM35YFC	Exocrine pancreatic insufficiency	DC35.1	Phase 1/2	[13]
AZM-131	DMLCSRF	Obesity	5B81	Terminated	[14]
B-Octylglucoside	DMMO75G	Discovery agent	N.A.	Investigative	[6]
(Hydroxyethyloxy)Tri(Ethyloxy)Octane	DMY6FUD	Discovery agent	N.A.	Investigative	[6]
B-Nonylglucoside	DM48VJR	Discovery agent	N.A.	Investigative	[15]
METHOXYUNDECYLPHOSPHINIC ACID	DMY0O7X	Discovery agent	N.A.	Investigative	[15]
Daio-Orengedokuto (DOT)	DM3M652	Discovery agent	N.A.	Investigative	[16]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Chymotrypsin (CTR)	TT7MRGU	NOUNIPROTAC	Modulator	[2]
Pancreatic alpha-amylase (AMY2A)	TTCGSZ4	AMYP_HUMAN	Modulator	[2]
Pancreatic triacylglycerol lipase (PNLIP)	TTXMY0J	LIPP_HUMAN	Modulator	[2]

References

• [1] ClinicalTrials.gov (NCT00500084) Phase III ALTU-135 CP Safety Trial. U.S. National Institutes of Health.
• [2] Clinical pipeline report, company report or official report of Anthera Pharmaceuticals.
• [3] US patent application no. 2012,0251,516, PHARMACEUTICAL COMPOSITION FOR TREATING CANCER COMPRISING TRYPSINOGEN AND/OR CHYMOTRYPSINOGEN AND AN ACTIVE AGENT SELECTED FROM A SELENIUM COMPOUND, A VANILLOID COMPOUND AND A CYTOPLASMIC GLYCOLYSIS REDUCTION AGENT.
• [4] Drugmakers dance with autism. Nat Biotechnol. 2010 Aug;28(8):772-4.
• [5] Clinical pipeline report, company report or official report of Digestive Care.
• [6] How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
• [7] Four acarviosin-containing oligosaccharides identified from Streptomyces coelicoflavus ZG0656 are potent inhibitors of alpha-amylase. Carbohydr Res. 2008 Apr 7;343(5):882-92.
• [8] DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41.
• [9] Chemistry, physiological properties, and microbial production of hydroxycitric acid. Appl Microbiol Biotechnol. 2007 Jul;75(5):977-82.
• [10] Enzymatic synthesis of a selective inhibitor for alpha-glucosidases: alpha-acarviosinyl-(1-->9)-3-alpha-D-glucopyranosylpropen. J Agric Food Chem. 2008 Jul 9;56(13):5324-30.
• [11] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [12] Pfizer. Product Development Pipeline. March 31 2009.
• [13] Clinical pipeline report, company report or official report of AzurRx.
• [14] US patent application no. 7217,697, Glucopyranosyloxypyrazole derivative medicinal composition containing the same medicinal use thereof and intermediate therefor.
• [15] The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
• [16] Daio-Orengedokuto inhibits HMG-CoA reductase and pancreatic lipase. Biol Pharm Bull. 2002 Nov;25(11):1442-5.